A randomized trial of brimonidine versus timolol in preserving visual function: Results from the low-pressure glaucoma treatment study

Theodore Krupin, Jeffrey M. Liebmann, David Greenfield, Robert Ritch, Stuart Gardiner

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Purpose: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma. Design Randomized, double-masked, multicenter clinical trial. Methods Exclusion criteria included untreated intraocular pressure (IOP) >21 mm Hg, visual field mean deviation worse than -16 decibels, or contraindications to study medications. Both eyes received twice-daily monotherapy randomized in blocks of 7 (4 brimonidine to 3 timolol). Standard automated perimetry and tonometry were performed at 4-month intervals. Main outcome measure was field progression in either eye, defined as the same 3 or more points with a negative slope <-1 dB/year at P < 5%, on 3 consecutive tests, assessed by pointwise linear regression. Secondary outcome measures were progression based on glaucoma change probability maps (GCPM) of pattern deviation and the 3-omitting method for pointwise linear regression. Results Ninety-nine patients were randomized to brimonidine and 79 to timolol. Mean (± SE) months of follow-up for all patients was 30.0 ± 2. Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P = .001). Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points. More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P = .008). Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method. Conclusion Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.

Original languageEnglish
Pages (from-to)671-681
Number of pages11
JournalAmerican Journal of Ophthalmology
Volume151
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Timolol
Glaucoma
Pressure
Linear Models
Therapeutics
Visual Fields
Intraocular Pressure
Adrenergic alpha-2 Receptor Agonists
Outcome Assessment (Health Care)
Visual Field Tests
Adrenergic beta-Antagonists
Brimonidine Tartrate
Manometry
Drug-Related Side Effects and Adverse Reactions
Multicenter Studies
Hypersensitivity
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A randomized trial of brimonidine versus timolol in preserving visual function : Results from the low-pressure glaucoma treatment study. / Krupin, Theodore; Liebmann, Jeffrey M.; Greenfield, David; Ritch, Robert; Gardiner, Stuart.

In: American Journal of Ophthalmology, Vol. 151, No. 4, 01.04.2011, p. 671-681.

Research output: Contribution to journalArticle

@article{f737420984754b0390a175ef4703225e,
title = "A randomized trial of brimonidine versus timolol in preserving visual function: Results from the low-pressure glaucoma treatment study",
abstract = "Purpose: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2{\%} to the beta-adrenergic antagonist timolol maleate 0.5{\%} in preserving visual function in low-pressure glaucoma. Design Randomized, double-masked, multicenter clinical trial. Methods Exclusion criteria included untreated intraocular pressure (IOP) >21 mm Hg, visual field mean deviation worse than -16 decibels, or contraindications to study medications. Both eyes received twice-daily monotherapy randomized in blocks of 7 (4 brimonidine to 3 timolol). Standard automated perimetry and tonometry were performed at 4-month intervals. Main outcome measure was field progression in either eye, defined as the same 3 or more points with a negative slope <-1 dB/year at P < 5{\%}, on 3 consecutive tests, assessed by pointwise linear regression. Secondary outcome measures were progression based on glaucoma change probability maps (GCPM) of pattern deviation and the 3-omitting method for pointwise linear regression. Results Ninety-nine patients were randomized to brimonidine and 79 to timolol. Mean (± SE) months of follow-up for all patients was 30.0 ± 2. Statistically fewer brimonidine-treated patients (9, 9.1{\%}) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2{\%}, log-rank 12.4, P = .001). Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points. More brimonidine-treated (28, 28.3{\%}) than timolol-treated (9, 11.4{\%}) patients discontinued study participation because of drug-related adverse events (P = .008). Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method. Conclusion Low-pressure glaucoma patients treated with brimonidine 0.2{\%} who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5{\%}.",
author = "Theodore Krupin and Liebmann, {Jeffrey M.} and David Greenfield and Robert Ritch and Stuart Gardiner",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.ajo.2010.09.026",
language = "English",
volume = "151",
pages = "671--681",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - A randomized trial of brimonidine versus timolol in preserving visual function

T2 - Results from the low-pressure glaucoma treatment study

AU - Krupin, Theodore

AU - Liebmann, Jeffrey M.

AU - Greenfield, David

AU - Ritch, Robert

AU - Gardiner, Stuart

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma. Design Randomized, double-masked, multicenter clinical trial. Methods Exclusion criteria included untreated intraocular pressure (IOP) >21 mm Hg, visual field mean deviation worse than -16 decibels, or contraindications to study medications. Both eyes received twice-daily monotherapy randomized in blocks of 7 (4 brimonidine to 3 timolol). Standard automated perimetry and tonometry were performed at 4-month intervals. Main outcome measure was field progression in either eye, defined as the same 3 or more points with a negative slope <-1 dB/year at P < 5%, on 3 consecutive tests, assessed by pointwise linear regression. Secondary outcome measures were progression based on glaucoma change probability maps (GCPM) of pattern deviation and the 3-omitting method for pointwise linear regression. Results Ninety-nine patients were randomized to brimonidine and 79 to timolol. Mean (± SE) months of follow-up for all patients was 30.0 ± 2. Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P = .001). Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points. More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P = .008). Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method. Conclusion Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.

AB - Purpose: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma. Design Randomized, double-masked, multicenter clinical trial. Methods Exclusion criteria included untreated intraocular pressure (IOP) >21 mm Hg, visual field mean deviation worse than -16 decibels, or contraindications to study medications. Both eyes received twice-daily monotherapy randomized in blocks of 7 (4 brimonidine to 3 timolol). Standard automated perimetry and tonometry were performed at 4-month intervals. Main outcome measure was field progression in either eye, defined as the same 3 or more points with a negative slope <-1 dB/year at P < 5%, on 3 consecutive tests, assessed by pointwise linear regression. Secondary outcome measures were progression based on glaucoma change probability maps (GCPM) of pattern deviation and the 3-omitting method for pointwise linear regression. Results Ninety-nine patients were randomized to brimonidine and 79 to timolol. Mean (± SE) months of follow-up for all patients was 30.0 ± 2. Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P = .001). Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points. More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P = .008). Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method. Conclusion Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%.

UR - http://www.scopus.com/inward/record.url?scp=79952984499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952984499&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2010.09.026

DO - 10.1016/j.ajo.2010.09.026

M3 - Article

C2 - 21257146

AN - SCOPUS:79952984499

VL - 151

SP - 671

EP - 681

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -